Ramucirumab Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03650764	Washington University School of Medicine Eli Lilly and Company	Head and Neck Squamous Cell Carcinoma	29-May-19	Phase 1 Phase 2
NCT02730247	Liza Villaruz, MD University of Pittsburgh	Non-small Cell Lung Cancer	5-Jul-17	Phase 2
NCT00703326	Eli Lilly and Company	Breast Cancer	6-Aug-08	Phase 3
NCT01017731	Eli Lilly and Company	Cancer Solid Tumor	Nov-09	Phase 2
NCT03281369	Hoffmann-La Roche Halozyme	Gastric Adenocarcinoma or Gastroesophageal	13-Oct-17	Phase 1 Phase 2
	Therapeutics BioLineRx, Ltd.	Junction Adenocarcinoma or Esophageal Carcinoma		
NCT04915807	Hallym University Medical Center	Gastric Cancer Gastroesophageal Junction Adenocarcinoma	Jun-21	
NCT01703091	Eli Lilly and Company	Non-small Cell Lung Cancer Metastatic	Dec-12	Phase 2
NCT02435433	Eli Lilly and Company	Hepatocellular Carcinoma	20-Jul-15	Phase 3
NCT03686488	H. Lee Moffitt Cancer Center and Research Institute	Gastric Adenocarcinoma Gastroesophageal	20-Dec-18	Phase 2
		Junction Adenocarcinoma Gastric Cancer		
NCT02411448	Eli Lilly and Company	Metastatic Non-Small Cell Lung Cancer	6-May-15	Phase 3
NCT04310007	National Cancer Institute (NCI)	Metastatic Lung Non-Squamous Non-Small Cell Carcinoma Recurrent Lung Non-Squamous	22-May-20	Phase 2
		Non-Small Cell Carcinoma Stage III Lung Cancer		
		AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB	}	
		Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC		
		v8 Stage IVA Lung Cancer AJCC v8 Unresectable		
		Lung Non-Squamous Non-Small Cell Carcinoma		
NCT04069273	Harry H Yoon Merck Sharp & Dohme Corp. Mayo	Gastric Cancer Gastro Esophageal	1-Dec-20	Phase 2
	Clinic Hoosier Cancer Research Network	Cancer Adenocarcinoma		
NCT03909334	Xiuning Le M.D. Anderson Cancer Center Eli Lilly	Non Small Cell Lung Cancer EGFR Gene	25-Jul-19	Phase 2
	and Company Hoosier Cancer Research Network	Mutation Advanced Cancer Metastatic Cancer		
NCT02079636	Eli Lilly and Company Merck Sharp & Dohme Corp.	Carcinoma, Non-small Cell Lung	28-Mar-14	Phase 1
NCT02314117	Eli Lilly and Company	Metastatic Gastric	20-Jan-15	Phase 3
		Adenocarcinoma Gastroesophageal Junction Adenocarcinoma		
NCT03921671	Marina Garassino Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Thymic Carcinoma Thymoma	1-Nov-18	Phase 2
NCT04145349	Eli Lilly and Company	Desmoplastic Small Round Cell Tumor	22-Jan-20	Phase 1 Phase 2

NCT04921904	Baylor Research Institute	Metastatic Esophageal Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma	Jun-21	Phase 1 Phase 2
NCT04495478	Eli Lilly and Company	Healthy	30-Jul-20	Phase 1
NCT04040361	Masahiro Tsuboi Merck Sharp & Dohme Corp. Eli Lilly and Company National Cancer Center Hospital East	Non-small Cell Lung Cancer Stage IB Non-small Cell Lung Cancer Stage II Non-small Cell Lung Cancer Stage ?A	30-Nov-19	Phase 2
NCT02581215	Walid Shaib, MD Eli Lilly and Company Hoosier Cancer Research Network	Pancreatic Cancer	Aug-16	Phase 2
NCT03745430	Hellenic Cooperative Oncology Group Eli Lilly and Company Celgene Corporation	Pancreatic Adenocarcinoma	29-Jan-19	Phase 1 Phase 2
NCT02307812	Eli Lilly and Company	Gastric Cancer Gastroesophageal Junction Adenocarcinoma		
NCT02443324	Eli Lilly and Company Merck Sharp & Dohme Corp.	Gastric Adenocarcinoma Adenocarcinoma of the Gastroesophageal Junction Non-small Cell Lung Cancer Carcinoma, Transitional Cell Biliary Tract Cancer	29-Jul-15	Phase 1
NCT04179110	Yale University	Transitional Cell Carcinoma	18-Sep-20	Phase 2
NCT02359058	Eli Lilly and Company	Stomach Neoplasms	Feb-15	Phase 1
NCT03013218	ALX Oncology Inc.	Metastatic Cancer Solid Tumor Advanced Cancer NonHodgkin Lymphoma	3-Feb-17	Phase 1
NCT02791334	Eli Lilly and Company	Solid Tumor Microsatellite Instability-High (MSI-H) Solid Tumors Cutaneous Melanoma Pancreatic Cancer Breast Cancer (HR&additionHER2-)	29-Jun-16	Phase 1
NCT00786383	Eli Lilly and Company	Cancer	Feb-06	Phase 1
NCT04394624	Sanofi	Non-small Cell Lung Cancer Metastatic	31-Aug-20	Phase 2
NCT04499924	Seagen Inc.	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma	22-Mar-21	Phase 2 Phase 3
NCT01005355	Eli Lilly and Company Parexel	Advanced Solid Tumors	Sep-09	Phase 1
NCT05062980	Genprex, Inc.	Non Small Cell Lung Cancer	Dec-21	Phase 1 Phase 2
NCT02082210	Eli Lilly and Company	Advanced Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Hepatocellular Cancer Renal Cell Carcinoma Non-Small Cell Lung Cancer	7-Mar-14	Phase 1 Phase 2
NCT02597036	Eli Lilly and Company	Solid Tumors	6-Nov-15	Phase 1
NCT02789345	Eli Lilly and Company AstraZeneca	Non-small Cell Lung Cancer	24-Oct-16	Phase 1

NCT03872947	Toray Industries, Inc	Solid Tumor Colon Cancer Cholangiocarcinoma Bladder Cancer Ovarian Cancer Gastric Cancer Palpable Subcutaneous Malignant Lesions Renal Cell Carcinoma Melanoma	April 26, 2019	Phase 1
NCT04151563	Bristol-Myers Squibb Clovis Oncology, Inc. Exelixis Eli Lilly and Company	Carcinoma, Non-small Cell Lung Cancer	April 15, 2021	Phase 1 Phase 2
NCT03527108	Fox Chase Cancer Center Bristol-Myers Squibb Eli Lilly and Company	Non Small Cell Lung Cancer	8-Oct-20	Phase 2
NCT01682135	Eli Lilly and Company	Solid Tumor	Nov-12	Phase 1
NCT04332367	Abramson Cancer Center of the University of Pennsylvania	Non-small Cell Lung Cancer	19-Dec-19	Phase 2
NCT02711553	Eli Lilly and Company	Biliary Tract Cancer Metastatic Cancer Advanced Cancer	19-May-16	Phase 2
NCT03560973	Gruppo Oncologico Italiano di Ricerca Clinica	Mesothelioma	22-Dec-16	Phase 2
NCT04205968	Southwest Oncology Group National Cancer Institute (NCI)	Metastatic Small Intestinal Adenocarcinoma Stage III Small Intestinal Adenocarcinoma AJCC v8 Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 Stage IV Small Intestinal Adenocarcinoma AJCC v8	16-Dec-19	Phase 2
NCT03694002	Southwest Oncology Group National Cancer Institute (NCI)	Locally Advanced Thymic Carcinoma Metastatic Thymic Carcinoma Recurrent Thymic Carcinoma Unresectable Thymic Carcinoma	9-Aug-18	Phase 2
NCT03760822	Federation Francophone de Cancerologie Digestive Eli Lilly and Company	Stomach Cancer Stomach Neoplasm Gastric Cancer Gastroesophageal Junction Adenocarcinoma	16-Nov-18	Phase 2
NCT03995017	Anwaar Saeed Bristol-Myers Squibb Clovis Oncology, Inc. University of Kansas Medical Center	Esophagus Cancer, Adenocarcinoma Stomach Cancer, Adenocarcinoma	9-Jan-20	Phase 1 Phase 2
NCT00735696	Eli Lilly and Company	Non Small Cell Lung Cancer	Jan-09	Phase 2
NCT02572687	Eli Lilly and Company AstraZeneca	Gastric Cancer Gastroesophageal Junction Adenocarcinoma Non-Small Cell Lung Cancer Hepatocellular Carcinoma	19-Feb-16	Phase 1
NCT01567163	Eli Lilly and Company	Malignant Solid Tumor	Jul-12	Phase 2
NCT03689855	Washington University School of Medicine Eli Lilly and Company	Non-small Cell Lung Cancer Non Small Cell Lung Cancer NSCLC	5-Jun-19	Phase 2
NCT01168973	Eli Lilly and Company	Non-Small Cell Lung Cancer	Dec-10	Phase 3
NCT05002127	ALX Oncology Inc. Eli Lilly and Company	Gastric Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma	Aug-21	Phase 2 Phase 3
NCT04145700	Eli Lilly and Company	Synovial Sarcoma	4-Mar-20	Phase 1 Phase 2

NCT03762564	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Eli Lilly and Company Trium Analysis Online GmbH	Squamous Cell Carcinoma of the Esophagus	8-Mar-19	Phase 2
NCT02934464	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Stomach Neoplasms	Dec-16	Phase 3
NCT01285037	Eli Lilly and Company	Cancer	9-Sep-09	Phase 1
NCT02678182	Royal Marsden NHS Foundation Trust MedImmune LLC Clovis Oncology, Inc. Eli Lilly and Company	Adenocarcinoma of the Oesophagus Adenocarcinoma of the Gastro-oesophageal Junction Adenocarcinoma of the Stomach	Feb-15	Phase 2
NCT02426125	Eli Lilly and Company	Urothelial Carcinoma	13-Jul-15	Phase 3
NCT02970539	Athenex, Inc.	Gastric Cancer Esophageal Cancer Gastro-esophageal Cancer	8-Dec-16	Phase 1
NCT02726399	Memorial Sloan Kettering Cancer Center	Gastric Cancer Gastroesophageal Junction Cancer	r 18-Mar-16	Phase 2
NCT00793975	Eli Lilly and Company	Advanced Solid Tumors	Jan-05	Phase 1
	Eli Lilly and Company	Malignant Solid Tumor	19-Jul-12	Phase 2
NCT01256567	Eli Lilly and Company	Breast Cancer Metastatic Breast Cancer	Dec-10	Phase 1
NCT04517747	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Gastric Adenocarcinoma Metastatic Adenocarcinoma of the Gastroesophageal Junction	15-Oct-20 N	ot Applicable
NCT00627042	Eli Lilly and Company	Hepatocellular Carcinoma	Feb-08	Phase 2
	Eli Lilly and Company National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd.			Phase 2 ase 1 Phase 2
NCT02999295	National Cancer Center, Japan Ono Pharmaceutical	Gastric Cancer Gastroesophageal Junction Region		
NCT02999295 NCT04632459	National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd.	Gastric Cancer Gastroesophageal Junction Region (GEJ) Cancer	1-Mar-21 April 6, 2020 Ph	ase 1 Phase 2
NCT02999295 NCT04632459 NCT03739801	National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd. Samsung Medical Center University of Southern California National Cancer	Gastric Cancer Gastroesophageal Junction Region (GEJ) Cancer Gastric Cancer Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction	1-Mar-21 April 6, 2020 Ph	ase 1 Phase 2 Phase 2
NCT02999295 NCT04632459 NCT03739801 NCT01983878	National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd. Samsung Medical Center University of Southern California National Cancer Institute (NCI) Ipsen	Gastric Cancer Gastroesophageal Junction Region (GEJ) Cancer Gastric Cancer Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	1-Mar-21 April 6, 2020 Ph	Phase 2 Phase 2 ase 1 Phase 2
NCT02999295 NCT04632459 NCT03739801 NCT01983878 NCT02628951	National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd. Samsung Medical Center University of Southern California National Cancer Institute (NCI) Ipsen	Gastric Cancer Gastroesophageal Junction Region (GEJ) Cancer Gastric Cancer Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Gastric Cancer Gastric Adenocarcinoma Gastroesophageal	1-Mar-21 April 6, 2020 Ph Dec-13	Phase 2 Phase 2 ase 1 Phase 2
NCT02999295 NCT04632459 NCT03739801 NCT01983878 NCT02628951 NCT00721162	National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd. Samsung Medical Center University of Southern California National Cancer Institute (NCI) Ipsen Eli Lilly and Company Samsung Medical Center	Gastric Cancer Gastroesophageal Junction Region (GEJ) Cancer Gastric Cancer Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Ovarian Cancer Fallopian Tube Cancer Primary	Dec-13 26-May-16	Phase 2 Phase 2 ase 1 Phase 2 Phase 2 Phase 2 Phase 2
NCT02999295 NCT04632459 NCT03739801 NCT01983878 NCT02628951 NCT00721162 NCT02069041	National Cancer Center, Japan Ono Pharmaceutical Co. Ltd Fiverings Co., Ltd. Samsung Medical Center University of Southern California National Cancer Institute (NCI) Ipsen Eli Lilly and Company Samsung Medical Center Eli Lilly and Company	Gastric Cancer Gastroesophageal Junction Region (GEJ) Cancer Gastric Cancer Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma	Dec-13 26-May-16 April 6, 208	Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2

NCT04704934	Daiichi Sankyo, Inc. AstraZeneca	Gastric Cancer, Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	21-May-21	Phase 3
	Arog Pharmaceuticals, Inc.	Esophagogastric Adenocarcinoma	April 14, 2017	Phase 1
NCT04340882	Emory University National Cancer Institute (NCI) Merck Sharp & Dohme Corp.	Metastatic Non-Small Lung Cell Cancer Recurrent Non-Small Lung Cell Cancer Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8		Phase 2
NCT03141034	Washington University School of Medicine Eli Lilly and Company	Gastric Adenocarcinoma Gastro-esophageal Junction Adenocarcinoma	1-Nov-17	Phase 2
NCT02745769	Eli Lilly and Company	Advanced Cancer Colorectal Cancer Mantle Cell Lymphoma	21-Oct-16	Phase 1
NCT03704077	Bristol-Myers Squibb	Gastric Cancer Cancer of the Stomach Stomach Cancer Gastroesophageal Junction	31-Oct-19	Phase 2
NCT02520141	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Cholangiocarcinoma Liver and Intrahepatic Bile Duct Carcinoma Stage III Gallbladder Cancer AJCC v7 Stage III Intrahepatic Cholangiocarcinoma AJCC v7 Stage IIIA Gallbladder Cancer AJCC v7 Stage IIIB Gallbladder Cancer AJCC v7 Stage IVA Gallbladder Cancer AJCC v7 Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7 Stage IVB Gallbladder Cancer AJCC v7 Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7 Unresectable Gallbladder Carcinoma		Phase 2
NCT02065765	Eli Lilly and Company	Metastatic Gastric Cancer Metastatic Adenocarcinoma of the Gastroesophageal Junction		
NCT02898077	Eli Lilly and Company	Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma	2-Mar-17	Phase 3
NCT03520946	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Eli Lilly and Company Trium Analysis Online GmbH	Colorectal Cancer	24-Jan-19	Phase 3
NCT02443883	Eli Lilly and Company	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	7-Jul-15	Phase 2
NCT02213289	University of Chicago AbbVie	Adenocarcinoma	20-Jan-15	Phase 2
NCT01140347	Eli Lilly and Company	Hepatocellular Carcinoma	Oct-10	Phase 3

Clinical Stage III Gastric Cancer AJCC v8 | Clinical 16-Jun-21

Stage III Gastroesophageal Junction

Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric

Cancer AJCC v8 | Clinical Stage IV

Gastroesophageal Junction Adenocarcinoma AJCC

v8 | Clinical Stage IVA Gastric Cancer AJCC

v8 | Clinical Stage IVA Gastroesophageal Junction

Adenocarcinoma AJCC v8 | Clinical Stage IVB

Gastric Cancer AJCC v8 | Clinical Stage IVB

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Locally Advanced Unresectable Gastric

Adenocarcinoma | Locally Advanced Unresectable

Gastroesophageal Junction

Adenocarcinoma | Metastatic Gastric

Adenocarcinoma | Metastatic Gastroesophageal

Junction Adenocarcinoma | Pathologic Stage III

Gastric Cancer AJCC v8 | Pathologic Stage III

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Pathologic Stage IIIA Gastric Cancer AJCC

v8|Pathologic Stage IIIA Gastroesophageal

Junction Adenocarcinoma AJCC v8 | Pathologic

Stage IIIB Gastric Cancer AJCC v8 | Pathologic

Stage IIIB Gastroesophageal Junction

Adenocarcinoma AJCC v8 | Pathologic Stage IIIC

Gastric Cancer AJCC v8 | Pathologic Stage IV

Gastric Cancer AJCC v8 | Pathologic Stage IV

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Pathologic Stage IVA Gastroesophageal

Junction Adenocarcinoma AJCC v8 | Pathologic

Stage IVB Gastroesophageal Junction

Adenocarcinoma AJCC v8 | Postneoadjuvant

Therapy Stage III Gastric Cancer AJCC

v8|Postneoadjuvant Therapy Stage III

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Postneoadjuvant Therapy Stage IIIA

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Postneoadjuvant Therapy Stage IIIB

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Postneoadjuvant Therapy Stage IV Gastric

Cancer AJCC v8 | Postneoadjuvant Therapy Stage

IV Gastroesophageal Junction Adenocarcinoma

AJCC v8 | Postneoadjuvant Therapy Stage IVA

Gastroesophageal Junction Adenocarcinoma AJCC

v8|Postneoadjuvant Therapy Stage IVB

Gastroesophageal Junction Adenocarcinoma AJCC

v8

NCT00533702	Eli Lilly and Company	Metastatic Malignant Melanoma	Nov-07	Phase 2
	Yonsei University	Recurrent+Metastatic Gastric Cancer	13-Feb-18	Phase 1 Phase 2
NCT02709626	Novartis Pharmaceuticals Novartis	Colorectal Cancer Gastroesophageal	22 May 10	Phase 1
NC103798020	NOVALUS PHAITHACEULICAIS NOVALUS	Cancer Renal Cell Carcinoma	22-May-19	Filase 1
NCT01170663	Eli Lilly and Company	Gastric Cancer	Dec-10	Phase 3
NCT01111604	Eli Lilly and Company	Colon Cancer Rectal Cancer	Aug-10	Phase 2
NCT05007769	Washington University School of Medicine Eli Lilly and Company ImmunityBio, Inc.	Non-small Cell Lung Cancer Non-small Cell Carcinoma NSCLC Non Small Cell Lung Cancer	31-Oct-21	Phase 2
NCT00895180	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) Eli Lilly and Company	Adult Glioblastoma Multiforme	Jul-10	Phase 2
NCT03971474	Southwest Oncology Group National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	17-May-19	Phase 2
NCT01427933	Eli Lilly and Company	Breast Cancer	Nov-11	Phase 2
NCT04675983	Innovent Biologics (Suzhou) Co. Ltd.	Gastric Adenocarcinoma	10-Mar-21	Phase 3
NCT02514551	Eli Lilly and Company	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	12-Oct-15	Phase 2
NCT03081143	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Advanced Gastric or EGJ Cancer	10-May-17	Phase 2 Phase 3
NCT03904108	ROGER S MD KERESZTES Stony Brook University	Carcinoma, Non-Small-Cell Lung	27-Jun-19	Phase 2
NCT04120454	Ohio State University Comprehensive Cancer Center National Cancer Institute (NCI)	Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	16-Mar-20	Phase 2
NCT02831491	Eli Lilly and Company	Stage IV Non-small Cell Lung Cancer	Nov-16	Phase 2
NCT02317991	SCRI Development Innovations, LLC Celgene	Gastroesophageal Cancer	5-May-15	Phase 2
NCT05071053	Sanofi	Adenocarcinoma Gastric Gastrooesophageal Cancer	15-Oct-21	Phase 2
NCT04557384	Eli Lilly and Company	Advanced Solid Tumor	23-Feb-21	Phase 1
NCT02539225	Eli Lilly and Company	Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	5-Oct-15	Phase 2
NCT00917384	Eli Lilly and Company	Gastric Cancer Adenocarcinoma	Aug-09	Phase 3
NCT00683475	Eli Lilly and Company	Prostate Cancer	Aug-08	Phase 2
NCT00515697	Eli Lilly and Company	Metastatic Renal Cell Carcinoma	Nov-07	Phase 2
NCT01183780	Eli Lilly and Company	Colorectal Cancer	2-Dec-10	Phase 3
NCT01224402	Eli Lilly and Company	Breast Cancer	Mar-11	Phase 2

NCT01282463	Eli Lilly and Company	Carcinoma of Urinary Tract Urethral Carcinoma Carcinoma of Ureter Carcinoma of Renal Pelvis	April 2011	Phase 2
NCT01160744	Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	Sep-10	Phase 2
NCT00862784	Eli Lilly and Company	Colorectal Carcinoma	April 2009	Phase 2
NCT03766607	Korean South West Oncology Group	Gastric Cancer	30-Sep-19	Phase 2
NCT01253525	Eli Lilly and Company	Adenocarcinoma	Nov-10	Phase 1
NCT01246986	Eli Lilly and Company	Carcinoma, Hepatocellular	30-Mar-11	Phase 2
NCT03863587	Shanghai Henlius Biotech	Healthy Male Volunteers	6-Jun-19	Phase 1
NCT03502746	Arkadiusz Z. Dudek, MD HealthPartners Institute Regions Cancer Care Center Eli Lilly and Company Bristol-Myers Squibb Hoosier Cancer Research Network	Mesothelioma, Malignant	26-Jun-18	Phase 2
NCT01634555	Eli Lilly and Company	Solid Tumors	Oct-12	Phase 2
NCT03008278	National Cancer Institute (NCI)	Metastatic Esophageal Carcinoma Metastatic Gastric Carcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Gastroesophageal Junction Adenocarcinoma Stage III Esophageal Cancer AJCC v7 Stage III Gastric Cancer AJCC v7 Stage IIIA Esophageal Cancer AJCC v7 Stage IIIA Gastric Cancer AJCC v7 Stage IIIB Esophageal Cancer AJCC v7 Stage IIIB Gastric Cancer AJCC v7 Stage IIIC Esophageal Cancer AJCC v7 Stage IIIC Gastric Cancer AJCC v7 Stage IV Esophageal Cancer AJCC v7 Stage IV Gastric Cancer AJCC v7 Unresectable Esophageal Carcinoma Unresectable Gastric Carcinoma Unresectable Gastroesophageal Junction Adenocarcinoma		Phase 1 Phase 2
NCT01079780	Eastern Cooperative Oncology Group National Cancer Institute (NCI)	Colorectal Cancer	8-Oct-10	Phase 2
NCT02795858	Dana-Farber Cancer Institute Eli Lilly and Company	Carcinoid Tumors	14-Jun-16	Phase 2
NCT02661971	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Stomach Cancer Gastroesophageal Junction Cancer	Jun-16 F	Phase 2 Phase 3
NCT02564198	Eli Lilly and Company Children's Oncology Group	Pediatric Solid Tumor Refractory Tumor Recurrent Tumor CNS Malignancies	11-Dec-15	Phase 1
NCT03966118	P. C. Thuss-Patience Charite University, Berlin, Germany	Gastroesophageal Junction Adenocarcinoma Adenocarcinoma of the Stomach	April 1, 2019	Phase 2

NCT04267913 Southwest Oncology Group | National Cancer Institute (NCI)

Lung Squamous Cell Carcinoma|Recurrent Lung 5-Sep-20
Carcinoma|Stage IV Lung Cancer AJCC v8|Stage
IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer
AJCC v8

Phase 2